Investors
BioAxone is poised to revolutionize the way spinal cord injury is treated. The company is currently privately financed and has grown a strong pipeline from non-dilutive grant financing.
BioAxone is building on the following value:
- Experienced management
- Exceptional clinical results with BioAxone’s lead product, Cethrin™, that show safety and efficacy
- Validated science
- Over 14 issued patents (US and Global)
- Key partnerships to build the business
- Understanding of translational medicine to bring additional new drugs forward to clinical testing
- Successful NIH/SBIR funding and a strong pipeline
For information on investments in SCI click here
For more information and investment opportunities, please contact:
Dr. Lisa McKerracher
Chief Executive Officer
(617) 401 3115
lmck@bioaxonebio.com